RECRUITING

Kidney Cancer DNA Registry

Conditions

Renal Cancer Questionnaire DNA saliva kidney cancer 13-218 high risk

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This registry will help us develop better methods of: * Preventing these cancers * Diagnosing these cancers * Treating these cancers

Official Title

Kidney Cancer DNA Registry

Quick Facts

Study Start:2014-03

Study Completion:2026-03

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT02087852

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Must be ≥ 18 years of age AND * Must be an English-speaker AND * Must have a diagnosis or suspicion of kidney cancer * Must be ≥ 18 years of age AND * Must be an English-speaker AND * Must be a blood relative of the proband. Family members of probands including mother, father, sisters, brothers, half-sisters, half-brothers, daughters, sons, grandmothers, grandfathers, as well as aunts and uncles are eligible. These individuals need not have kidney cancer, as they will be used for segregation analysis of suspected variants found in the proband; requesting DNA from relatives is required. * Must be ≥ 18 years of age AND * Must be an English-speaker AND * Must not have a personal history of cancer, with the exception of nonmelanoma skin cancer, AND * Must not be a blood relative of any cases or controls enrolled in this study	* Patients who, in the opinion of the primary MSKCC clinician or the investigator, have a condition that precludes their ability to provide an informed consent

Inclusion Criteria

Exclusion Criteria

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must have a diagnosis or suspicion of kidney cancer
* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must be a blood relative of the proband. Family members of probands including mother, father, sisters, brothers, half-sisters, half-brothers, daughters, sons, grandmothers, grandfathers, as well as aunts and uncles are eligible. These individuals need not have kidney cancer, as they will be used for segregation analysis of suspected variants found in the proband; requesting DNA from relatives is required.
* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must not have a personal history of cancer, with the exception of nonmelanoma skin cancer, AND
* Must not be a blood relative of any cases or controls enrolled in this study

* Patients who, in the opinion of the primary MSKCC clinician or the investigator, have a condition that precludes their ability to provide an informed consent

Contacts and Locations

Study Contact

Jonathan Coleman, MD

CONTACT

646-422-4432

Kenneth Offit, MD

CONTACT

646-888-4050

Principal Investigator

Jonathan Jonathan, MD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (Consent and Follow up)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Consent and Follow up )

Montvale, New Jersey, 07645

United States

Memorial Sloan Kettering Commack (Consent and Follow-up)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Consent and Follow up)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Consent and Follow-Up)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Jonathan Jonathan, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-03

Study Completion Date2026-03

Study Record Updates

Study Start Date2014-03

Study Completion Date2026-03

Terms related to this study

Keywords Provided by Researchers

Questionnaire
DNA
saliva
kidney cancer
13-218
high risk

Additional Relevant MeSH Terms

Renal Cancer